JP2017504590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504590A5 JP2017504590A5 JP2016538745A JP2016538745A JP2017504590A5 JP 2017504590 A5 JP2017504590 A5 JP 2017504590A5 JP 2016538745 A JP2016538745 A JP 2016538745A JP 2016538745 A JP2016538745 A JP 2016538745A JP 2017504590 A5 JP2017504590 A5 JP 2017504590A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- eudragit
- item
- linaclotide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 174
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 claims description 46
- 108010024409 linaclotide Proteins 0.000 claims description 46
- 229960000812 linaclotide Drugs 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 36
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 24
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 24
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 22
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 20
- 206010010774 Constipation Diseases 0.000 claims description 18
- 230000003111 delayed effect Effects 0.000 claims description 17
- 208000010643 digestive system disease Diseases 0.000 claims description 17
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000009505 enteric coating Methods 0.000 claims description 15
- 239000002702 enteric coating Substances 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 210000003405 ileum Anatomy 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 10
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 10
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 10
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 10
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 210000001072 colon Anatomy 0.000 claims description 9
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 208000009935 visceral pain Diseases 0.000 claims description 7
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 238000009498 subcoating Methods 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920003143 Eudragit® FS 30 D Polymers 0.000 claims description 5
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims description 5
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- -1 Plasacryl® Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 5
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000007784 diverticulitis Diseases 0.000 claims description 5
- 201000006549 dyspepsia Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 5
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940068196 placebo Drugs 0.000 claims description 4
- 239000000902 placebo Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000003243 intestinal obstruction Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920006254 polymer film Polymers 0.000 claims description 3
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 2
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 206010054048 Postoperative ileus Diseases 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000024798 heartburn Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 150000001768 cations Chemical class 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000000087 stabilizing effect Effects 0.000 description 9
- 239000011575 calcium Substances 0.000 description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
- 206010017999 Gastrointestinal pain Diseases 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000007950 delayed release tablet Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical group [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 description 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032177 Intestinal Polyps Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078445A JP7483656B2 (ja) | 2013-12-11 | 2021-05-06 | リナクロチドの遅延放出組成物 |
| JP2023115832A JP2023126475A (ja) | 2013-12-11 | 2023-07-14 | リナクロチドの遅延放出組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914952P | 2013-12-11 | 2013-12-11 | |
| US201361914951P | 2013-12-11 | 2013-12-11 | |
| US61/914,951 | 2013-12-11 | ||
| US61/914,952 | 2013-12-11 | ||
| PCT/US2014/069838 WO2015089326A1 (en) | 2013-12-11 | 2014-12-11 | Delayed release compositions of linaclotide |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019029432A Division JP2019073559A (ja) | 2013-12-11 | 2019-02-21 | リナクロチドの遅延放出組成物 |
| JP2021078445A Division JP7483656B2 (ja) | 2013-12-11 | 2021-05-06 | リナクロチドの遅延放出組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504590A JP2017504590A (ja) | 2017-02-09 |
| JP2017504590A5 true JP2017504590A5 (enExample) | 2018-01-25 |
| JP6964380B2 JP6964380B2 (ja) | 2021-11-10 |
Family
ID=52293217
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538745A Active JP6964380B2 (ja) | 2013-12-11 | 2014-12-11 | リナクロチドの遅延放出組成物 |
| JP2019029432A Pending JP2019073559A (ja) | 2013-12-11 | 2019-02-21 | リナクロチドの遅延放出組成物 |
| JP2021078445A Active JP7483656B2 (ja) | 2013-12-11 | 2021-05-06 | リナクロチドの遅延放出組成物 |
| JP2023115832A Pending JP2023126475A (ja) | 2013-12-11 | 2023-07-14 | リナクロチドの遅延放出組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019029432A Pending JP2019073559A (ja) | 2013-12-11 | 2019-02-21 | リナクロチドの遅延放出組成物 |
| JP2021078445A Active JP7483656B2 (ja) | 2013-12-11 | 2021-05-06 | リナクロチドの遅延放出組成物 |
| JP2023115832A Pending JP2023126475A (ja) | 2013-12-11 | 2023-07-14 | リナクロチドの遅延放出組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US20160310560A1 (enExample) |
| EP (2) | EP3821881A1 (enExample) |
| JP (4) | JP6964380B2 (enExample) |
| KR (3) | KR102337809B1 (enExample) |
| CN (3) | CN115089556A (enExample) |
| AU (3) | AU2014362220B2 (enExample) |
| CA (1) | CA2933587C (enExample) |
| CL (1) | CL2016001424A1 (enExample) |
| CY (1) | CY1123953T1 (enExample) |
| DK (1) | DK3079669T3 (enExample) |
| EA (1) | EA201691216A1 (enExample) |
| EC (2) | ECSP16059106A (enExample) |
| ES (1) | ES2838007T3 (enExample) |
| HR (1) | HRP20201753T1 (enExample) |
| HU (1) | HUE052981T2 (enExample) |
| IL (2) | IL246155A0 (enExample) |
| LT (1) | LT3079669T (enExample) |
| MX (2) | MX386584B (enExample) |
| NZ (2) | NZ759512A (enExample) |
| PE (2) | PE20211976A1 (enExample) |
| PH (1) | PH12016501122B1 (enExample) |
| PL (1) | PL3079669T3 (enExample) |
| PT (1) | PT3079669T (enExample) |
| RS (1) | RS61133B1 (enExample) |
| SG (2) | SG10201804817TA (enExample) |
| SI (1) | SI3079669T1 (enExample) |
| SM (1) | SMT202000686T1 (enExample) |
| UA (1) | UA119335C2 (enExample) |
| WO (2) | WO2015089326A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2016125064A1 (en) * | 2015-02-02 | 2016-08-11 | Aurobindo Pharma Ltd | Stable compositions comprising linaclotide |
| WO2016197042A1 (en) * | 2015-06-05 | 2016-12-08 | Ironwood Pharmaceuticals, Inc. | Modified or targeted release formulations of linaclotide |
| US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2017156214A1 (en) * | 2016-03-11 | 2017-09-14 | Gateway Pharmaceutical LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2018065826A1 (en) * | 2016-10-06 | 2018-04-12 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| MA47112A (fr) * | 2016-12-21 | 2019-10-30 | Ironwood Pharmaceuticals Inc | Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide |
| KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
| BR112020019128A2 (pt) * | 2018-03-23 | 2021-01-12 | Palatin Technologies, Inc. | Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN114206324A (zh) * | 2019-06-10 | 2022-03-18 | 硬木药品公司 | 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛 |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| CN110935007B (zh) * | 2019-12-12 | 2023-06-23 | 烟台大学 | 利那洛肽复方组合物、制剂及其用途和制备方法 |
| GB202017863D0 (en) * | 2020-11-12 | 2020-12-30 | Intract Pharma Ltd | Novel compositions |
| EP4340838A4 (en) * | 2021-05-19 | 2025-04-16 | Alberto Paz | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT |
| WO2024076577A1 (en) * | 2022-10-03 | 2024-04-11 | Brim Biotechnology, Inc. | Compositions comprising pedf-derived short peptides (pdsp) and uses thereof |
| JPWO2024143501A1 (enExample) * | 2022-12-28 | 2024-07-04 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN201252259Y (zh) * | 2008-07-24 | 2009-06-03 | 富士康(昆山)电脑接插件有限公司 | 电连接器 |
| NZ591713A (en) * | 2008-08-15 | 2013-07-26 | Ironwood Pharmaceuticals Inc | Solid stable formulations of linaclotide for oral administration |
| US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
| JP2013501071A (ja) * | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ， インコーポレイテッド | リナクロチドを含む処方物 |
| MX2012001691A (es) * | 2009-08-12 | 2012-02-29 | Forest Lab Holdings Ltd | Composiciones de linaclotida que se desintegran oralmente. |
| WO2011020054A1 (en) * | 2009-08-13 | 2011-02-17 | Ironwood Pharmaceuticals Inc. | Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| PL2536742T3 (pl) * | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
| EP3626253B8 (en) * | 2010-08-11 | 2022-04-20 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| WO2012034068A1 (en) * | 2010-09-11 | 2012-03-15 | Ironwood Pharmaceuticals, Inc. | Treatment of constipation-predominant irritable bowel syndrome |
| JP2012155108A (ja) * | 2011-01-26 | 2012-08-16 | Kyocera Document Solutions Inc | 現像ローラ、現像装置および画像形成装置 |
| DK2776055T3 (en) * | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| BR112014007753B1 (pt) * | 2011-09-30 | 2021-07-06 | Astellas Pharma Inc. | composição farmacêutica granular, formulação e método para produção |
| US20140018307A1 (en) * | 2012-07-12 | 2014-01-16 | Forest Laboratories Holdings Ltd. | Linaclotide compositions |
| EP3718557A3 (en) * | 2013-02-25 | 2020-10-21 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
-
2014
- 2014-11-12 UA UAA201607434A patent/UA119335C2/uk unknown
- 2014-12-11 MX MX2016007625A patent/MX386584B/es unknown
- 2014-12-11 CN CN202210517834.4A patent/CN115089556A/zh active Pending
- 2014-12-11 SG SG10201804817TA patent/SG10201804817TA/en unknown
- 2014-12-11 CA CA2933587A patent/CA2933587C/en active Active
- 2014-12-11 US US15/103,634 patent/US20160310560A1/en not_active Abandoned
- 2014-12-11 KR KR1020167018606A patent/KR102337809B1/ko active Active
- 2014-12-11 LT LTEP14824655.6T patent/LT3079669T/lt unknown
- 2014-12-11 HU HUE14824655A patent/HUE052981T2/hu unknown
- 2014-12-11 SM SM20200686T patent/SMT202000686T1/it unknown
- 2014-12-11 RS RS20201435A patent/RS61133B1/sr unknown
- 2014-12-11 NZ NZ759512A patent/NZ759512A/en unknown
- 2014-12-11 NZ NZ721952A patent/NZ721952A/en unknown
- 2014-12-11 JP JP2016538745A patent/JP6964380B2/ja active Active
- 2014-12-11 CN CN201480075352.1A patent/CN106659687A/zh active Pending
- 2014-12-11 PT PT148246556T patent/PT3079669T/pt unknown
- 2014-12-11 DK DK14824655.6T patent/DK3079669T3/da active
- 2014-12-11 EP EP20198666.8A patent/EP3821881A1/en active Pending
- 2014-12-11 SG SG11201604729QA patent/SG11201604729QA/en unknown
- 2014-12-11 ES ES14824655T patent/ES2838007T3/es active Active
- 2014-12-11 AU AU2014362220A patent/AU2014362220B2/en active Active
- 2014-12-11 WO PCT/US2014/069838 patent/WO2015089326A1/en not_active Ceased
- 2014-12-11 PE PE2021000748A patent/PE20211976A1/es unknown
- 2014-12-11 HR HRP20201753TT patent/HRP20201753T1/hr unknown
- 2014-12-11 KR KR1020237008167A patent/KR20230039764A/ko not_active Ceased
- 2014-12-11 EA EA201691216A patent/EA201691216A1/ru unknown
- 2014-12-11 WO PCT/US2014/069851 patent/WO2015089335A1/en not_active Ceased
- 2014-12-11 PH PH1/2016/501122A patent/PH12016501122B1/en unknown
- 2014-12-11 PL PL14824655T patent/PL3079669T3/pl unknown
- 2014-12-11 KR KR1020217039962A patent/KR102509291B1/ko active Active
- 2014-12-11 CN CN202011156517.1A patent/CN112569199A/zh active Pending
- 2014-12-11 EP EP14824655.6A patent/EP3079669B1/en active Active
- 2014-12-11 US US15/103,616 patent/US20160310559A1/en not_active Abandoned
- 2014-12-11 SI SI201431715T patent/SI3079669T1/sl unknown
- 2014-12-11 PE PE2016000804A patent/PE20161373A1/es unknown
-
2016
- 2016-06-09 IL IL246155A patent/IL246155A0/en unknown
- 2016-06-10 MX MX2021011906A patent/MX2021011906A/es unknown
- 2016-06-10 CL CL2016001424A patent/CL2016001424A1/es unknown
- 2016-07-08 EC ECIEPI201659106A patent/ECSP16059106A/es unknown
-
2017
- 2017-02-17 US US15/435,701 patent/US20170157200A1/en not_active Abandoned
- 2017-09-28 US US15/718,075 patent/US20180015139A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029432A patent/JP2019073559A/ja active Pending
- 2019-09-11 US US16/567,082 patent/US20200038476A1/en not_active Abandoned
-
2020
- 2020-04-01 AU AU2020202319A patent/AU2020202319B2/en active Active
- 2020-11-26 CY CY20201101128T patent/CY1123953T1/el unknown
-
2021
- 2021-05-06 IL IL283012A patent/IL283012A/en unknown
- 2021-05-06 JP JP2021078445A patent/JP7483656B2/ja active Active
- 2021-09-28 EC ECSENADI202172161A patent/ECSP21072161A/es unknown
- 2021-10-18 US US17/503,601 patent/US20220031802A1/en not_active Abandoned
-
2022
- 2022-03-18 AU AU2022201891A patent/AU2022201891A1/en not_active Abandoned
-
2023
- 2023-07-14 JP JP2023115832A patent/JP2023126475A/ja active Pending
- 2023-11-09 US US18/505,414 patent/US20240075094A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504590A5 (enExample) | ||
| JP7483656B2 (ja) | リナクロチドの遅延放出組成物 | |
| JP2014524444A5 (enExample) | ||
| CN105025888B (zh) | 肠溶片 | |
| JP2022093472A (ja) | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 | |
| US20230346878A1 (en) | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | |
| JP2018516937A5 (enExample) | ||
| HK40081509A (en) | Delayed release compositions of linaclotide | |
| HK40017265A (en) | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide | |
| HK1237651A1 (en) | Delayed release compositions of linaclotide |